Sep 8, 2026 —
Bristol Myers Squibb has reported positive Phase 2 results for arlo-cel, an investigational GPRC5D-directed chimeric antigen receptor (CAR) T-cell therapy, in patients with relapsed or refractory multiple myeloma.
According to the company, the therapy improved response rates in heavily pretreated patients who had received at least four prior lines of therapy. GPRC5D is an alternative target to BCMA, the antigen addressed by currently approved myeloma CAR-T therapies, and could offer an option for patients who progress after BCMA-directed treatment.
Detailed trial data were not included in the initial report.